Avant and Ainnova Explore Dementia Detection for Vision AI Platform

by:
|
June 19, 2025

Avant Technologies, Inc. (OTCQB: AVAI) and its joint venture partner, Ainnova Tech, Inc., announced their exploration of integrating early dementia detection into Ainnova’s Vision AI platform, aiming to enhance their AI-driven preventive health solutions globally.

Quick Intel

Avant and Ainn DTS explore dementia detection for Vision AI platform.
Patented technology uses AI and a 5-minute blood test for early detection.
Vision AI currently screens for cardiovascular, diabetes, liver, and kidney risks.
Potential licensing or acquisition of dementia detection technology.
Aims to enhance global preventive health solutions via Ai-nova Acquisition Corp.
FDA pre-submission meeting for Vision AI set for July 7, 2025.

Expanding Vision AI with Dementia Detection

Avant Technologies and Ainnova Tech are exploring the integration of a patented early dementia detection technology into Ainnova’s Vision AI platform, which currently uses retinal imaging, blood pressure, and lab data to assess risks for cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease. The new technology, combining AI algorithms with a 5-minute blood test, aims to enhance the platform’s capabilities, aligning with their mission to lead in early disease detection globally.

Strategic Partnership and Technology Integration

The companies are considering licensing or acquiring this dementia detection technology to expand their preventive health portfolio. “This accessible, fast, and scalable solution is designed to support early intervention and targeted treatment strategies, with the ambition of reaching millions of patients globally,” said Vinicio Vargas, CEO of Ainnova and board member of Ai-nova Acquisition Corp., the joint venture managing the platform’s global licensing. This move follows their ongoing efforts to advance Vision AI, with an FDA pre-submission meeting scheduled for July 7, 2025, to discuss clinical trials for diabetic retinopathy detection.

Proven Impact and Global Ambitions

Ainnova’s Vision AI platform, recognized with multiple global awards, integrates low-cost retinal imaging devices with AI to deliver comprehensive risk screening. Pilot programs in Chile and the Dominican Republic have demonstrated cost reductions, improved resource allocation, and enhanced profitability for healthcare providers. The potential addition of dementia detection aims to further revolutionize preventive healthcare by enabling early intervention for millions worldwide.

Regulatory and Market Progress

The partnership, operating through Ai-nova Acquisition Corp., is navigating FDA regulatory pathways to bring Vision AI to the U.S. market, with the July 2025 meeting critical for defining clinical trial parameters. Recent posts on X reflect growing excitement, with Avant and Ainnova’s merger discussions and Vision AI’s expansion into Mexico signaling strong market momentum.

The collaboration between Avant Technologies and Ainnova to integrate early dementia detection into Vision AI positions them to transform preventive healthcare. By leveraging AI and innovative blood testing, they aim to deliver scalable, accessible solutions, enhancing global health outcomes and solidifying their leadership in AI-driven diagnostics.

About Ainnova Tech, Inc.

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

About Avant Technologies, Inc.

Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

Share

Join 30,000+ Avid Tech Readers!

Trending tech news, interviews & insights straight to your inbox.

I agree to the Privacy Policy terms

Avant and Ainnova Explore Dementia Detection for Vision AI Platform

Quick Intel

Expanding Vision AI with Dementia Detection

Strategic Partnership and Technology Integration

Proven Impact and Global Ambitions

Regulatory and Market Progress

About Ainnova Tech, Inc.

About Avant Technologies, Inc.

Join 30,000+ Avid Tech Readers!

About Us

Quick Links

Connect With Us

Search TechIntelPro

Subscribe to Our Newsletter

Avant and Ainnova Explore Dementia Detection for Vision AI Platform

Quick Intel

Expanding Vision AI with Dementia Detection

Strategic Partnership and Technology Integration

Proven Impact and Global Ambitions

Regulatory and Market Progress

About Ainnova Tech, Inc.

About Avant Technologies, Inc.

Join 30,000+ Avid Tech Readers!

About Us

Quick Links

Connect With Us